Paradigm Downgrades Biovail (BVF) to Hold
More News related to BVF
- Biovail to Participate at Upcoming Investor Conferences
- BMO Upgrades Biovail (BVF) to Outperform
- Canaccord Starts Biovail (BVF) at Buy; $14 PT
- Notable Mergers and Acquisitions of the Day 9/17: SNDK, LDG/WAG, BVF
- Biovail (BVF) Acquires Prestwick Pharma for $100M
More News related to Downgrades
- Citi Downgrades G&K Services (GKSR) to Hold
- Merrill Lynch Downgrades G&K Services (GKSR) to Underperform
- JP Morgan Downgrades Murphy Oil (MUR) to Underweight
- JP Morgan Downgrades Suncor Energy (SU) to Underweight
- JPMorgan Downgrades Forest Laboratories (FRX) to Underweight
Paradigm downgrades Biovail Corp. (NYSE: BVF) from Buy to Hold and lowers its price target from $20 to $11.25.
Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing various drug-delivery technologies in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
